U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H14N2O5
Molecular Weight 242.229
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TELBIVUDINE

SMILES

Cc1cn([C@]2([H])C[C@]([H])([C@]([H])(CO)O2)O)c(=O)nc1O

InChI

InChIKey=IQFYYKKMVGJFEH-CSMHCCOUSA-N
InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1

HIDE SMILES / InChI

Molecular Formula C10H14N2O5
Molecular Weight 242.229
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: http://www.drugbank.ca/drugs/DB01265

mitochondrial toxicity was observed in HepG2 cells treated with telbivudine at concentrations up to 10 µM.

CNS Activity

Originator

Curator's Comment:: Telbivudine was originally developed by US company Idenix, and Novartis licensed rights to the product in 2003 in a 25 million deal. Novartis is also working with Idenix on another hepatitis B product candidate, valtorcitabine, which is in Phase II testing.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q05486
Gene ID: NA
Gene Symbol: P
Target Organism: Hepatitis B virus genotype F2 (isolate Brazil/w4B) (HBV-F)
1.3 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TYZEKA

Approved Use

TYZEKA™ (telbivudine) is indicated for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

Launch Date

1200096000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.2 μg/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.22 μg/mL
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.61 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.97 μg/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5.46 μg/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.82 μg/mL
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.99 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.24 μg/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.69 μg/mL
600 mg 1 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.56 μg × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.75 μg × h/mL
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.91 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
20.94 μg × h/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
29.73 μg × h/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.14 μg × h/mL
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5.02 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6.67 μg × h/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
26.1 μg × h/mL
600 mg 1 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
44.5 h
600 mg 1 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
96.7%
600 mg 1 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELBIVUDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1800 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1800 mg, 1 times / day
Sources:
healthy, adult
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Disc. AE: CK increased, Nausea...
AEs leading to
discontinuation/dose reduction:
CK increased (4%)
Nausea (4%)
Diarrhea (4%)
Fatigue (4%)
Myalgia (4%)
Myopathy (4%)
Sources:
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Other AEs: Acute hepatitis B, Lactic acidosis...
Other AEs:
Acute hepatitis B (severe)
Lactic acidosis (severe|grade 5)
Hepatomegaly (severe|grade 5)
Sources:
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Disc. AE: CK increased, Nausea...
AEs leading to
discontinuation/dose reduction:
CK increased (6 patients)
Nausea (2 patients)
Diarrhea (4 patients)
Fatigue (2 patients)
Myalgia (2 patients)
Myopathy (1 patient)
Pain in extremity (1 patient)
Nasopharyngitis (1 patient)
Hepatic pain (1 patient)
Gastroenteritis (1 patient)
Gastritis (1 patient)
Dyspnea (1 patient)
Dizziness (1 patient)
Blood potassium decreased (1 patient)
Asthenia (1 patient)
Anosmia (1 patient)
Amenorrhea (1 patient)
ALT increased (1 patient)
Abdominal tenderness (1 patient)
Abdominal pain (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
CK increased 4%
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Diarrhea 4%
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Fatigue 4%
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Myalgia 4%
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Myopathy 4%
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Nausea 4%
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Acute hepatitis B severe
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Hepatomegaly severe|grade 5
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Lactic acidosis severe|grade 5
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
ALT increased 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Abdominal pain 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Abdominal tenderness 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Amenorrhea 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Anosmia 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Asthenia 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Blood potassium decreased 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Dizziness 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Dyspnea 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Gastritis 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Gastroenteritis 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Hepatic pain 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Myopathy 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Nasopharyngitis 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Pain in extremity 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Fatigue 2 patients
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Myalgia 2 patients
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Nausea 2 patients
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Diarrhea 4 patients
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
CK increased 6 patients
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B.
2006
Treating chronic hepatitis B: today and tomorrow.
2006
Looking to the future: new agents for chronic hepatitis B.
2006
[Progress in the treatment of chronic hepatitis B with Telbivudine].
2006 Dec
Management of chronic hepatitis B virus infection: a new era of disease control.
2006 Feb
Cellular and virological mechanisms of HBV drug resistance.
2006 Feb
Gateways to clinical trials.
2006 Jan-Feb
Telbivudine: a novel nucleoside analog for chronic hepatitis B.
2006 Mar
Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects.
2006 Mar
Special considerations and treatment of patients with HBV-HIV coinfection.
2007
Enantio-selectivity of human nucleoside monophosphate kinases.
2007
In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
2007
Telbivudine.
2007 Apr
Time for an active antiviral therapy for hepatitis B: An update on the management of hepatitis B virus infection.
2007 Aug
Customizing the management of chronic hepatitis B virus infection.
2007 Aug
The role of entecavir in the treatment of chronic hepatitis B.
2007 Dec
Clinical implications of resistance patterns against HBV-polymerase inhibitors for the treatment of chronic hepatitis B.
2007 Dec
Treatment of Hepatitis B e Antigen-negative Patients.
2007 Dec
Telbivudine for the management of chronic hepatitis B virus infection.
2007 Dec
[The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].
2007 Dec
Telbivudine: a new treatment for chronic hepatitis B.
2007 Dec 14
Telbivudine versus lamivudine in patients with chronic hepatitis B.
2007 Dec 20
Summaries for patients. Antiviral therapy for chronic hepatitis B.
2007 Dec 4
New drugs: sitagliptin phosphate, telbivudine, and panitumumab.
2007 Jan-Feb
[Treatment in every detected virus replication. New guideline for therapy of hepatitis B publicized].
2007 Jul 19
[New first line therapy of chronic hepatitis B. Primary therapy goal: effective virus suppression].
2007 Jul 19
[Advances in the treatment of hepatitis B].
2007 Jul-Aug
Treatment of chronic hepatitis B in HIV-infected patients in 2007.
2007 Mar
New and emerging treatment of chronic hepatitis B.
2007 Mar
Telbivudine for the treatment of chronic hepatitis B.
2007 May
Gateways to clinical trials.
2007 Nov
Therapy of chronic hepatitis B: focus on telbivudine.
2007 Nov
Management and treatment of chronic hepatitis B virus: Belgian Association for the Study of the Liver (BASL) 2007 guidelines.
2007 Oct-Dec
Gateways to clinical trials.
2007 Sep
[Telbivudine in the treatment of the chronic B hepatitis].
2008 Apr
Telbivudine versus lamivudine in patients with chronic hepatitis B.
2008 Apr 3
Telbivudine: new drug. Chronic hepatitis B: similar to lamivudine.
2008 Feb
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
2008 Feb
[Anti-viral therapy of type B chronic hepatitis. 3. Future of anti-viral agents].
2008 Jan 10
Gateways to clinical trials.
2008 Jan-Feb
Review article: current antiviral therapy of chronic hepatitis B.
2008 Jul
Current antiviral therapies for chronic hepatitis B.
2008 Jun
[New treatment options in chronic hepatitis B].
2008 Mar
[Pharmacological agents for the treatment of chronic hepatitis B].
2008 Mar
Chronic hepatitis B: preventing, detecting, and managing viral resistance.
2008 Mar
Active antiviral therapy for chronic hepatitis B and hepatocellular carcinoma.
2008 Mar
New drugs for chronic hepatitis B: a review.
2008 Mar-Apr
[Chinese roadmap for treating chronic hepatitis B with telbivudine].
2008 May
Hepatitis B goes globe: Telbivudine as a new treatment option.
2008 May
[New data and recommendations of antiviral therapy of chronic hepatitis B and C].
2008 Oct
Patents

Sample Use Guides

600 mg once-daily
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: This in vitro report confirms that telbivudine shows no in vitro antiviral effect against a broad range of wild-type and multi-drug resistant HIV isolates at IC50 values >600 μM, a value well above physiologically relevant concentrations and known to inhibit HBV activity in vitro (EC50 value = 200 nM). These results support further investigation in a clinical trial setting, of the efficacy and safety of telbivudine, for treatment of CHB in HIV-HBV co-infected patients who do not concurrently require anti-HIV treatment and for whom there are few available treatment options.
up to 600 μM
Substance Class Chemical
Created
by admin
on Sat Jun 26 10:57:50 UTC 2021
Edited
by admin
on Sat Jun 26 10:57:50 UTC 2021
Record UNII
2OC4HKD3SF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TELBIVUDINE
EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
LDT600
Code English
TELBIVUDINE [ORANGE BOOK]
Common Name English
TELBIVUDINE [INN]
Common Name English
LDT-600
Code English
TELBIVUDINE [VANDF]
Common Name English
2,4(1H,3H)-PYRIMIDINEDIONE,1-(2-DEOXY-.BETA.-L-ERYTHRO-PENTOFURANOSYL)-5-METHYL-
Common Name English
TYZEKA
Brand Name English
2'-DEOXY-L-THYMIDINE
Common Name English
TELBIVUDINE [USAN]
Common Name English
TELBIVUDINE [EMA EPAR]
Common Name English
TELBIVUDINE [MI]
Common Name English
TELBIVUDINE [WHO-DD]
Common Name English
NV-02B
Code English
SEBIVO
Brand Name English
TELBIVUDINE [MART.]
Common Name English
Classification Tree Code System Code
LIVERTOX 928
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
NCI_THESAURUS C97452
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
NDF-RT N0000175656
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
NDF-RT N0000175459
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
NDF-RT N0000175459
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
NDF-RT N0000009947
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
WHO-ATC J05AF11
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
EMA ASSESSMENT REPORTS SEBIVO (AUTHORIZED: HEPATITIS B, CHRONIC)
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
WHO-VATC QJ05AF11
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
NDF-RT N0000175459
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C66584
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
PRIMARY
DRUG BANK
DB01265
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
PRIMARY
CAS
3424-98-4
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
PRIMARY
EPA CompTox
3424-98-4
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
PRIMARY
FDA UNII
2OC4HKD3SF
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
PRIMARY
LACTMED
Telbivudine
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
PRIMARY
PUBCHEM
159269
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
PRIMARY
WIKIPEDIA
TELBIVUDINE
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
PRIMARY
EVMPD
SUB25231
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
PRIMARY
ChEMBL
CHEMBL374731
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
PRIMARY
RXCUI
474128
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
4220
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
PRIMARY
MERCK INDEX
M10528
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
PRIMARY Merck Index
INN
8296
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
PRIMARY
MESH
C487779
Created by admin on Sat Jun 26 10:57:50 UTC 2021 , Edited by admin on Sat Jun 26 10:57:50 UTC 2021
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
EXCRETED UNCHANGED
AMOUNT EXCRETED
FECAL
BINDER->LIGAND
BINDING
TARGET ORGANISM->INHIBITOR
EC50
TRANSPORTER -> NON-SUBSTRATE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

ONCE DAILY

Tmax PHARMACOKINETIC ORAL ADMINISTRATION

ONCE DAILY